Abstract
Cytoplasmic lipid droplets (CLD) are organelle-like structures that function in neutral lipid storage, transport and metabolism through the actions of specific surface-associated proteins. Although diet and metabolism influence hepatic CLD levels, how they affect CLD protein composition is largely unknown. We used non-biased, shotgun, proteomics in combination with metabolic analysis, quantitative immunoblotting, electron microscopy and confocal imaging to define the effects of low- and high-fat diets on CLD properties in fasted-refed mice. We found that the hepatic CLD proteome is distinct from that of CLD from other mammalian tissues, containing enzymes from multiple metabolic pathways. The hepatic CLD proteome is also differentially affected by dietary fat content and hepatic metabolic status. High fat feeding markedly increased the CLD surface density of perilipin-2, a critical regulator of hepatic neutral lipid storage, whereas it reduced CLD levels of betaine-homocysteine S-methyltransferase, an enzyme regulator of homocysteine levels linked to fatty liver disease and hepatocellular carcinoma. Collectively our data demonstrate that the hepatic CLD proteome is enriched in metabolic enzymes, and that it is qualitatively and quantitatively regulated by diet and metabolism. These findings implicate CLD in the regulation of hepatic metabolic processes, and suggest that their properties undergo reorganization in response to hepatic metabolic demands.
Introduction
Obesity, which is largely driven by excess calorie consumption, affects nearly 30% of the population in the United States [1] and is a chief etiological factor in development of metabolic disorders that underlie type II diabetes, cardiovascular and kidney diseases and non-alcoholic fatty liver disease [2]. As a major regulator of energy homeostasis, the liver is a primary target of obesity-associated metabolic alterations [3]; and disruption of hepatic lipid metabolism is proposed to play a fundamental role in the initiation and progression of many metabolic diseases [4], [5].
Abnormal intrahepatic fat accumulation (steatosis) in the form of cytoplasmic lipid droplets (CLD) is an early pathophysiological feature of altered liver metabolism that is linked to insulin resistance and potential progression to severe liver disease [6], [7]. CLD are organelle-like structures that are critically involved in the storage, trafficking and metabolic regulation of cellular neutral lipids [8]. Consequently, understanding how CLD affect hepatic metabolism, and how nutritional status impacts their functions, are important elements in defining the mechanistic links between hepatic steatosis and metabolic diseases. CLD are composed of a neutral lipid core, surrounded by a phospholipid monolayer, and coated by various proteins that regulate CLD functional properties [9]. Members of the perilipin (PLIN) family are among the most abundant CLD-associated proteins in mammalian cells, functioning as physiologically important regulators of cellular lipid metabolism and trafficking [10]. Gene disruption studies in mice have documented that perilipin-2 (Plin2, adipophilin, ADRP) is required for hepatic lipid accumulation in response to high fat diet (HFD) feeding [11]–[13]. However, other PLIN family members have been detected on hepatic CLD in humans and mice with fatty liver disease [14], [15], which suggests the possibility that diet and/or altered metabolic properties can dynamically influence hepatic CLD protein composition.
Protein compositions of CLD been characterized to varying degrees from multiple sources including; yeast (Saccharomyces cerevisiae) [16], [17], Drosophila [18]–[20], mouse mammary epithelial cells [21], Chinese hamster ovary K2 cell lines [22], [23], 3T3-L1 adipocytes [24], [25], cultured human A431 epithelial cells [26], HuH7 human hepatoma cell line [27], cultured human hepatocyte HepG2 cell lines [28], liver tissue from Sprague-Dawley rats [29] and mice [21], human lymphoblast U937 cells from lung tissue [30], and mouse skeletal muscle [31]. However, information about the protein composition of hepatic CLD remains relatively limited, and the effects of diet and/or metabolic alterations on CLD protein properties are not known in detail for any tissue.
The highly dynamic and adaptive nature of liver metabolism is sensitive to nutrient status [32]. In rodents, fasting and refeeding is associated with alterations in hepatic glucose and lipid metabolism that are reflected in increased expression of lipid metabolizing genes and the accumulation of intrahepatic lipids [33], [34]. The nature of these responses is influenced by the amount of and types of dietary fat [35]. In the work presented here, we use a fasting and refeeding model to test the hypothesis that the hepatic CLD proteome is influenced by dietary fat composition. Our data show that low fat (LF) and high fat (HF) diets differentially affect the types and quantities of CLD associated protein compositions, and that these differences are associated with differences in hepatic metabolism and CLD properties. Taken together these findings indicate the hepatic CLD proteome is dynamically regulated by the nutrient and metabolic status of the liver and provide evidence that CLD may function as a platform for regulating hepatic metabolic activity.
Methods
Ethics Statement
All procedures involving animals were performed in accordance with published National Institutes of Health Guidelines. The University of Colorado Anschutz Medical Campus Institutional Animal Care and Use Committee approved this study and all procedures and housing conditions used to complete it.
Materials
Chemicals used were purchased from Sigma Chemical Company (St. Louis, MO). Antibodies to N- and C-terminal regions of Plin2 and to Plin3 were raised in rabbits as described [36]. Guinea pig antibodies specific to the N-terminal 25 amino acids of mouse Plin2 were purchased from Fitzgerald (North Acton, MA). Rabbit antibodies to GRP78 and PDI were purchased from Novus Biologicals (Littleton, Colorado), and Fitzgerald Inc. (North Acton, MA) respectively. Rabbit anti-BHMT was purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Horseradish-peroxidase-conjugated and Alexfluor-conjugated secondary antibodies were purchased from Life Technologies (Grand Island, NY). IR dye-conjugated secondary antibodies were purchased from Li-COR Biosciences (Lincoln, Nebraska). High fat (60 kcal%; D12492) and low fat (10 kcal%, D12045B) diets were purchased from Research Diets Inc. (New Brunswick, NJ).
Animal procedures
Twelve-week-old C57BL/6 mice were fasted for 24 hours, with access to water ad libitum, and refed with LF (10.0% fat-derived calories, 24.0% protein-derived calories and 60% carbohydrate-derived calories) or HF (60.3% fat-derived calories, 18.4% protein-derived calories and 21.3% carbohydrate-derived calories) diets for 16 hours. Livers were removed from refed animals, euthanized by carbon dioxide, and weighed. A portion of each liver was removed and used for CLD isolation. The remaining portions were fixed in 4% paraformaldehyde and processed for paraffin imbedding [15] or flash frozen in liquid nitrogen for RNA and protein analyses.
Metabolic monitoring
Three separate cohorts of mice were placed in a metabolic monitoring system that provided measurements of energy balance (intake and expenditure), the respiratory exchange ratio (RER), and activity levels (Columbus 8M Oxymax) [37]. Mice were individually housed in metabolic chambers and allowed to acclimate for one week prior to fasting and refeeding.
CLD isolation
CLD were isolated from liver homogenates by sucrose gradient centrifugation as described previously [21]. Briefly, freshly dissected livers were homogenized on ice in an equal volume of ice cold homogenization buffer (37.5 mM TRIS-malate, pH 6.4; 0.5 M sucrose; and 5 mM MgCl2 pH 6.4 plus protease inhibitors (Aprotinin, Leupeptin, Peptstatin, AEBSF, PIC1, PIC2 ) using a Dounce homogenizer. The homogenate was centrifuged at 3000× g for 10 minutes at 4°C. CLD were isolated from the resulting postnuclear supernatant fraction by sucrose gradient centrifugation and washed by repeated (3X) floatation as described [21]. For proteomics analysis the CLD sample was diluted in 100 ul of 10 mM Tris pH 7.4. For western blot analysis the samples were diluted in 100 ul of 5% SDS in 10 mM Tris pH 7.4 plus protease inhibitors and stored in −80°C.
RNA extraction and transcript quantitation
Total RNA was extracted from frozen tissue using Trizol (Life Technologies) according to the manufacturer's instructions. The purity, concentration, and integrity of total RNA from each sample were verified using a NanoDrop spectrophotometer (NanoDrop Technologies, Wilmington, DE). Transcript copy numbers were determined by quantitative real-time (QRT)-PCR analysis using a multiplexing strategy to provide an internal standard for normalization (18s ribosomal). QRT-PCR assays were performed in the Quantitative Genomics Core Laboratory at the University of Texas Health Sciences Center as described previously [36] using validated primers and probes shown in Table S1. At least three tissue replicates were analyzed at least twice with similar results.
Protein extraction and quantitation
Protein concentrations in extracts and isolated fractions were measured using Bio-Rad Protein Assay (Hercules, CA). CLD-associated proteins were extracted in 5% SDS and stored at −80°C prior to analysis by SDS-PAGE and immunoblotting. Proteins were separated on 10% polyacrylamide gels and stained with Coomassie blue or transferred to nitrocellulose membranes for immunoblot analysis, using the following primary antibodies and dilutions. Guinea pig anti-Plin2 (1:1,000); rabbit anti-PDI (1:500); rabbit anti-GRP78 (1:1000); rabbit anti-BHMT (1:500). Infrared dye-conjugated secondary antibodies (Li-COR, Lincoln, Nebraska ) were used according to the manufacturer's specifications. Antibody staining intensity was quantified using an Odyssey CLX system.
In solution digest and LC-MS/MS
Protein from the isolated CLD was precipitated using methanol chloroform (1:2). After the protein pellet was dissolved in 2 ul of 1% Protease Max Surfactant in 50 mM ammonia bicarbonate (ABC) (Promega, Madison, WI), 83.5 ul of ABC was added to the sample followed by DTT to a final concentration of 5 mM. The sample was incubate for 20 minutes at 56°C and then cooled to RT. Iodoacetamide was added to a final concentration of 15 mM and incubated at RT in the dark for 15 minutes to block the sulfhydryl groups. A second addition of 1ul of 1% Protease Max Surfactant was added to the sample followed by 1ug of Trypsin (Promega, Madison, WI). The sample was digested overnight at 37°C. The condensate was collected by centrifugation at 12,000× g for 10 seconds. The reaction was quenched by the addition of trifluroacetic acid (TFA) to a final concentration of 0.5% and incubated for 5 minutes at RT. The samples were purified and concentrated using a 10 ul μ-c18 ZipTip (Millipore, CA) according to the manufactures directions. The peptides were eluted in 60%acetonitrile/0.1% formic acid. HPLC-MS/MS was performed by the University of Colorado, Anschutz Medical Campus Mass Spectrometry/Proteomics Core Facility. Samples were analyzed by microcapillary HPLC tandem mass spectrometry (μLC-MS/ΜS) using an LTQ XL mass spectrometer (Thermo, San Jose, CA). Samples (2.5 μL) were injected onto a reverse-phase column via a cooled (12°C) autosampler (Eksigent, Dublin, CA) connected to an HPLC system (Agilent 1100, Agilent Technologies, Santa Clara CA) that was set at 70 μL/min before the split and ∼350 nL/min after the split. HPLC buffers used were Buffer A: 94.9% water, 5% acetonitrile, and 0.1% formic acid and Buffer B: 94.9% acetonitrile, 5% water, and 0.1% formic acid. A 90-minute HPLC gradient was used to separate peptides. The gradient changed from 5% to 28% acetonitrile over 60 minutes followed by organic and aqueous washes on a 15 cm microcapillary HPLC column with a pulled 5 μm nanospray tip for nano-electrospray ionization. The column was packed in-house with reverse-phase stationary phase Synergi 4u, 100 Å C18 (Phenomenex, Torrance, CA). The column was heated to 60°C using a column heater constructed in-house.
Data acquisition
Mass spectrometry data acquisition was performed in data-dependent mode on the Xcalibur instrument software (v. 2.0.6, Thermo, San Jose, CA) with a single MS1 scan (30 ms) followed by up to three data dependent collision induced dissociation scans (MS/MS, 30 ms each). Data were converted from the Thermo *.raw data file format to the *.mgf format using an in-house script. After conversion, data were searched against the mouse Swissprot database (downloaded 12/14/2011) using Mascot® (v. 2.2.07, Matrix Science Ltd., Boston, MA). For searches, mass tolerances were set at ±0.60 Da for both MS peaks and MS/MS fragment ions. Trypsin enzyme specificity was applied allowing one missed cleavage in the database searches. Modifications searched included fixed carbamidomethyl modification of cysteine and the variable oxidation modifications of methionine, protein N-terminal acetylation, peptide N-terminal pyro-glutamic acid formation. Results from the Mascot searches were analyzed and sorted using Scaffold® (v. 3.00, Proteome Software, Portland, OR).
Immunohistochemistry and Fluorescence Imaging
Paraffin sections were processed for immunohistochemistry as described previously [38]. Immunoreactivity was visualized using secondary antibodies conjugated with Alexafluor 488 or Alexafluor 594 at dilutions of 1:500 and 1:250 respectively. Nuclei were stained with DAPI (Sigma Chemical Company, St Louis, MO). Immunofluorescence images were captured on a Nikon Diaphot fluorescence microscope.
For CARS microscopy and BODIPY staining, livers from refed animals were perfused with paraformaldehyde, sectioned at 10 um, collected onto Cell-Tak coated coverslips, and vapor-fixed with paraformaldehyde for 20 min before being gently rehydrated with PBS. Auto-fluorescence was quenched with 2 mg/ml glycine for 10 min. Sections were rinsed with PBS and stained with BODIPY 493/503 at a final concentration of 30 ug/ml, and DAPI at 5 ug/ml. Coverslips were mounted in PBS and imaged within 3 days. Confocal imaging of BODIPY 493/503 and DAPI was performed on a 3i Marianas Inverted Spinning Disk Confocal system. All image analyses and rendering were performed using SlideBook Software (Intelligent Imaging Innovations, Inc., Denver, CO). Coherent anti-Stokes Raman scattering (CARS) images of lipid droplets in tissue sections were acquired with a custom-built multiphoton microscopy platform optimized for CARS as previously described [39]. All images were processed by Photoshop (Adobe Systems Inc., Mountain View, CA).
Immunoelectron microscopy
Cells were processed for immunoelectron microscopy using a modified Tokuyasu method [40] as described previously [41]. Briefly, pelleted cells were fixed overnight at 4°C in PBS buffered 4% paraformaldehyde containing 5% sucrose and 100 mM HEPES, and infiltrated with PBS containing 2.1 M sucrose over ∼10 hours, with repeated solution changes. Fixed cells were transferred to an aluminum cryosectioning stub (Ted Pella, Inc., Redding, CA) and immediately frozen in liquid nitrogen. Semi-thin (90 nm) cryosections were cut at −110°C with an UltraCut UCT/FCS cryomicrotome (Leica), using a diamond knife (Diatome US) and transferred to a Formvar-coated, carbon-coated, glow-discharged 100-mesh copper-rhodium EM grid. Following blocking of non-specific antibody binding sites with 10% calf serum in PBS, the sections were labeled by sequential incubation with rabbit antibodies to the N-terminal domain of Plin2 [36] and colloidal gold conjugated secondary antibodies (Ted Pella Inc., Redding, CA) and then negatively stained and embedded with 1% uranyl acetate, 1% methylcellulose in distilled water. Samples were viewed in a Tecnai TF20 electron microscope (FEI) operating at 200 KeV and images collected digitally.
Statistical Analysis
Calculations were performed by using Prism 5.0 (GraphPad Software) and Microsoft Excel (Windows 2010, Microsoft). For each variable, 2 to 6 independent experiments were carried out. Differences between diet groups were tested for significance using an unpaired Student t test. Differences were considered significant at P≤0.05.
Bioinformatic Analysis
STRING 9.0 (http://string.embl.de/), Gene ontology database (http://geneontology.org/), and KEGG (http://www.genome.jp/kegg) were used for protein interaction, biological function, and pathway analysis respectively.
Results
Diet effects on metabolism and hepatic lipid storage
Fasting and diet composition are known to influence food intake and liver metabolism, which in turn can affect hepatic lipid storage [42], [43]. Therefore, to define the effects of LF and HF diets on hepatic CLD properties, it was necessary first to establish the effects of these diets on energy intake and metabolism of fasted animals. Figure 1A shows that energy consumption of fasted animals that were refed the HF diet was significantly greater than that of animals refed the LF diet. We also found differences in the fuel utilization properties of LF- and HF-refed animals. Figure 1B shows the respiratory exchange ratio (RER) values of mice prior to fasting, following a 24 hr period of fast, and after refeeding with LF- or HF-diets. Prior to fasting, RER values were approximately 0.8, as fuel use reflected the broad mixture of carbohydrate, fat, and protein in the diet. During fasting, RER values dropped to approximately 0.7, indicating a switch to fat as the primary source of energy. Refeeding on a LF diet resulted in RER values that were close to 1, reflecting the preferential use of carbohydrate for energy production and the likelihood that de novo lipogenesis was induced [37]. In contrast, mice refed the HF diet had RER values that remained closer to 0.7, which indicated they were oxidizing fat for energy, like fasted animals.
The distribution and properties of CLD in liver sections of LF- and HF-refed mice were visualized by coherent anti-Stokes Raman scattering (CARS) microscopy [44], and by confocal laser microscopy after staining neutral lipids with BODIPY (493/503) (Figure 1C). CLD were detected throughout the liver in both LF- and HF-refed animals, although both CARS and BODIPY intensities appeared to be greater in the central vein region (zone 3). Consistent with the elevated fat content of HF diets, we found that CARS and BODIPY intensities of livers of HF-refed animals were greater than those of LF-refed mice. CLD properties were further defined by 3D laser confocal microscopy of BODIPY stained liver sections. Representative 3D projection images of CLD from central vein regions of hepatocytes of LF- and HF-refed mice (Figure 1D), indicate that CLD are larger, and appear to be more numerous, in animals refed the HF diet relative to those refed the LF diet.
Diet effects on hepatic CLD protein composition
To determine if LF- and HF-CLD differed in their protein compositions, CLD were isolated from liver extracts by multiple rounds of floatation [21]. We have previously documented that CLD isolated by this procedure are free of membrane structures and other organelles [21]. Figure 2A shows that the CLD fraction is enriched in specific protein bands that differ significantly from those present in the starting homogenate. The relative purity of the CLD-enriched fraction was estimated by probing the homogenate, post nuclear supernatant (PNS), the initial CLD fraction, the 3rd (final) wash and final CLD fractions with antibodies to endoplasmic reticulum (GRP78), CLD (Plin2), peroxisome (PEX3), and mitochondria (VDAC) proteins. Figure 2B shows that Plin2 levels in the final CLD fraction were dramatically enriched over its levels in the starting homogenate and the initial CLD faction. We did not detect VDAC or PEX3 in the final CLD or in the final CLD wash fractions by immunoblot (Figure 2B) or by mass spectrometry analyses (see below), although both proteins were found in the homogenate and in initial CLD isolates. These results suggest that the final CLD fraction lacked significant mitochondria or peroxisome contamination, and that contaminating proteins in the initial CLD isolate were effectively removed by our floatation wash procedures. In contrast, and consistent with earlier proteomic evidence from other tissues and cell types [17], [45], we detected significant amounts GRP78 in the final CLD isolate. However, unlike fastidious CLD proteins such as Plin2, the relative levels GRP78 were not enriched in the final CLD isolate compared to the initial isolate and we continued to detect significant amounts of GRP78 in sucrose floatation wash fractions (Figure 2B). These observations indicate that GRP78 retains the ability to associate with hepatic CLD during their isolation; although its partial dissociation with each wash step suggests that the strength of this association is weaker than that of Plin2.
Liver Specific- and Common-CLD Associated Proteins
We used LC-MS/MS analysis of trypsin digests of CLD protein extracts as a non-biased “shotgun” approach for identifying the protein compositions of LF- and HF-CLD. Only those proteins with two or more unique peptides, and that were found in repeat analyses of isolated CLD from duplicate fasting-refeeding experiments, were accepted as valid identifications. Overall, we identified 125 proteins on CLD from mice refed the LF diet, and 134 proteins on CLD from mice refed the HF diet. The identified proteins, their biological functions according to Uniprot and GO database descriptions, and estimates of their relative abundance as determined by their percentage of total spectra, are shown in the Table S2.
Of the proteins found on either LF- or HF-CLD, 54 (36%) were identified previously on CLD from other mammalian sources (Table S3; the citations for these proteins are given in Table S2), and thus appear to represent common CLD associated proteins. Whereas, 98 proteins (64%) were not previously detected on CLD, and therefore potentially represent liver specific CLD associated proteins (Table S4). The functional categories of the common- and liver-specific CLD associated proteins are shown in Figure 3. Proteins involved in lipid metabolism (22%), redox/detoxification (17%) and chaperone functions (15%) accounted for over half of the common-CLD associated proteins, whereas enzymes of amino acid (27%) and carbohydrate metabolism (16%), and redox/detoxification (15%) pathways made up the majority of the liver-specific CLD associated proteins. We next used the STRING 9.0 program to examine the extent to which the identified proteins exhibited direct functional connections. As shown in Figure 3B, liver-specific proteins are organized into a series of discrete, interacting nodes, suggesting the existence of multiple functional linkages between nodes, and between proteins within a given node. Common-CLD associated proteins on the other hand appear to be less functionally related. We found that these proteins comprised only two non-interacting nodes; one related to protein processing, and another related to glycolysis.
We used the KEGG pathway database to further define potential functional interactions among common- and liver-specific CLD associated proteins (Table 1). We identified significant enrichment of common-CLD associated proteins in 9 KEGG pathways using a false discovery rate (FDR) value of p<0.05. The majority of the pathways are related to carbohydrate (4) and fatty acid metabolism (3), the others were related to amino acid metabolism (1) and protein processing (1). For liver-specific CLD associated proteins, we found significant enrichment in 26 KEGG pathway categories. Of these, 12 were related to amino acid metabolism, 6 were related to carbohydrate metabolism, 4 were related to fatty acid metabolism, 3 were related to xenobiotic metabolism and 1 was related to glutathione metabolism. Among the identified enzymes, several corresponded to large portions of the glycolysis/gluconeogenesis and cysteine/methonine pathways.
Table 1. Liver Specific- and Common-CLD Protein KEGG Pathways.
Liver Specific CLD associated proteins | ||||
KEGG ID | Pathway | Number Of Genes | P-value fdr | |
mmu00270 | Cysteine and methionine metabolism | 8 | 8.54E-07 | |
mmu00350 | Tyrosine metabolism | 7 | 1.44E-05 | |
mmu00330 | Arginine and proline metabolism | 8 | 1.73E-05 | |
mmu00010 | Glycolysis/Gluconeogenesis | 9 | 2.25E-05 | |
mmu00620 | Pyruvate metabolism | 7 | 2.25E-05 | |
mmu00360 | Phenylalanine metabolism | 5 | 2.26E-05 | |
mmu00071 | Fatty acid metabolism | 7 | 2.26E-05 | |
mmu00250 | Alanine, aspartate and glutamate metabolism | 6 | 3.61E-05 | |
mmu00982 | Drug metabolism – cytochrome P450 | 8 | 9.24E-05 | |
mmu03320 | PPAR signaling pathway | 8 | 9.24E-05 | |
mmu00400 | Phenylalanine, tyrosine and tryptophan biosynthesis | 3 | 1.37E-04 | |
mmu00980 | Metabolism of xenobiotics by cytochrome P450 | 7 | 3.10E-04 | |
mmu00480 | Glutathione metabolism | 6 | 6.03E-04 | |
mmu04146 | Peroxisome | 7 | 6.03E-04 | |
mmu00500 | Starch and sucrose metabolism | 5 | 9.90E-04 | |
mmu00450 | Selenoamino acid metabolism | 4 | 2.10E-03 | |
mmu00020 | Citrate cycle (TCA cycle) | 4 | 6.50E-03 | |
mmu00260 | Glycine, serine and threonine metabolism | 4 | 7.84E-03 | |
mmu00630 | Glyoxylate and dicarboxylate metabolism | 3 | 1.20E-02 | |
mmu00410 | beta-Alanine metabolism | 3 | 2.05E-02 | |
mmu00910 | Nitrogen metabolism | 3 | 2.05E-02 | |
mmu00280 | Valine, leucine and isoleucine degradation | 4 | 2.45E-02 | |
mmu00340 | Histidine metabolism | 3 | 2.78E-02 | |
mmu00030 | Pentose phosphate pathway | 3 | 4.16E-02 | |
mmu00903 | Limonene and pinene degradation | 2 | 4.24E-02 | |
mmu00640 | Propanoate metabolism | 3 | 4.24E-02 | |
Common CLD associated proteins | ||||
mmu04146 | Peroxisome | 6 | 8.95E-04 | |
mmu00010 | Glycolysis/Gluconeogenesis | 6 | 8.95E-04 | |
mmu00071 | Fatty acid metabolism | 4 | 9.00E-03 | |
mmu03320 | PPAR signaling pathway | 4 | 4.64E-02 | |
mmu00051 | Fructose and mannose metabolism | 3 | 4.64E-02 | |
mmu00650 | Butanoate metabolism | 3 | 4.64E-02 | |
mmu00380 | Tryptophan metabolism | 3 | 4.64E-02 | |
mmu00620 | Pyruvate metabolism | 3 | 4.64E-02 | |
mmu04612 | Antigen processing and presentation | 4 | 4.64E-02 |
Low- and High- Fat Specific CLD associated proteins
The functional classes of proteins that were uniquely associated with LF- and HF-CLD exhibited distinct patterns (Figure 4A). The majority of the proteins uniquely associated with LF-CLD are involved in amino acid (29%) and carbohydrate (23%) metabolism. Whereas, most of the uniquely associated proteins on HF-CLD are related to lipid metabolism and redox/detoxifcation processes. Using the STRING 9.0 program to probe for functionally interactions between LF- and HF-CLD specific proteins, we found that LF-CLD specific proteins formed a single high stringency interaction node connecting enzymes involved in amino acid and acetate metabolism. Whereas HF-CLD specific proteins formed a high stringency node related to redox/detoxification processes, and two sets of individual connections between pyruvate and carbohydrate metabolism, and between methione/cysteine and dicarboxylic acid metabolism (Figure 4B).
Among the 17 proteins specifically found on LF-CLD, we did not detect significant enrichment in any KEGG pathway. However for the 26 proteins specifically found on HF-CLD, there was enrichment in 5 KEGG pathways with FDR values <0.05; PPAR signaling, ascorbate metabolism, pyruvate metabolism, fatty acid metabolism and glyoxylate metabolism. The identities of the HF-CLD associated proteins found in enriched KEGG pathways are shown in Table 2.
Table 2. Specific HFD CLD Protein KEGG Pathways.
KEGG ID | Pathway | P-value (fdr) | Gene |
mmu00053 | Ascorbate and aldarate metabolism | 2.13E-03 | Gulo |
Aldh2 | |||
Ugt1a1 | |||
mmu03320 | PPAR signaling pathway | 7.47E-03 | Apoa1 |
Hmgcs2 | |||
Pck1 | |||
Cyp4a14 | |||
mmu00620 | Pyruvate metabolism | 1.37E-02 | Grhpr |
Pck1 | |||
Aldh2 | |||
mmu00071 | Fatty acid metabolism | 1.37E-02 | Acadvl |
Aldh2 | |||
Cyp4a14 | |||
mmu00630 | Glyoxylate and dicarboxylate metabolism | 4.73E-02 | Mthfd1 |
Grhpr |
Diet affects Plin2 CLD levels
In addition to finding qualitative differences in the protein compositions of LF- and HF-CLD, we found that LF and HF diets appeared to influence the relative abundance of some CLD-associated proteins, as suggested by differences in total spectra percentages (Table S2). One of these proteins was the CLD scaffolding protein, Plin2. To determine if spectra percentage differences observed for Plin 2 on LF- and HF-CLD reflected actual abundance differences, we investigated the effects of LF and HF-refeeding on hepatic Plin2 by confocal immunofluorescence (IF) microscopy, and by quantitative immunoblot analysis of isolated CLD (Figure 5). IF microscopy showed significant Plin2 immunostaining in livers of both LF- and HF-refed mice, with HF-refed mice exhibiting greater Plin2 staining intensities than LF-refed mice, particularly within central vein regions (Figure 5A). Quantitative immunoblot analyses showed that when compared to total CLD protein (Figure 5B), or to total CLD triglyceride (TG) levels (Figure 5C), HF-refeeding increased the average amount of Plin2 on CLD by approximately 4-fold over that found on CLD from LF-refed animals. HF refeeding did not increase the total amount of protein per unit of CLD TG (data not shown), which suggests that the enrichment of Plin2 on HF-CLD was not associated with a generalized increase in the protein content of CLD from HF-refed animals.
Fasting and HF diets are known to increase hepatic Plin2 transcript levels [46]. Thus, we were interested in determining whether differences in the relative abundance of Plin2 on LF- and HF-CLD reflected differences in the effects of LF and HF diets on hepatic Plin2 expression. As shown in Figure 5D, we found that Plin2 transcript levels in total hepatic RNA were similar for HF- and LF-refed mice. The data in Figure 5D also show that hepatic Plin2 transcript levels are several fold greater than those of other PLIN family members, and that hepatic expression levels of other PLIN family genes also were not influenced by the content of fat in the refeeding diet. Collectively, these data indicate that Plin2 is the most abundantly expressed member of the PLIN family in livers of fasted and refed mice, and that differences in the effects of LF- and HF-refeeding on CLD levels of Plin2 are unrelated to the effects of these diets on Plin2 expression.
High fat feeding increases Plin2 surface density on CLD
As a CLD surface associated protein, an increase in the relative amount of Plin2 on CLD could be due to loss of other CLD-associated proteins, or to absolute increases in its surface density. To address this issue, we quantified the effects of HF exposure on the CLD surface density of Plin2 by electron microscopy after labeling Plin2 with immuno-gold particles. For these experiments, we used Plin2 negative HEK293 cells that constitutively expresses recombinant mouse Plin2 under control of the CMV promoter [47] to avoid potential effects of fat exposure on Plin2 expression. Figure 5E shows that CLD in these cells increased in size following feeding with 100 μM oleic acid (OA), and that the number of anti-Plin2 conjugated-gold particles on the surface of individual CLD increased as a function of time in OA-supplemented media. The average CLD surface densities of Plin2 in cells incubated in control media without OA supplementation (T = 0 hr), or in cells supplemented with OA for 4 or 24 hrs are shown in the graph in Figure 5E. Plin2 surface densities in cells incubated in OA-supplemented medium were about 2-fold greater than their T0 values after 4 hrs (p<0.01), and approximately 6-fold greater after 24 hrs (p<0.001). These data provide direct evidence that the surface density of Plin2 on CLD is dynamically regulated and increased under conditions of high fat exposure.
Endoplasmic Reticulum (ER) Chaperone Proteins Localize to Hepatic CLD
ER proteins, including several with chaperone function, have been identified on isolated CLD from various mammalian cells and tissues [21], [22], [24], [26], [48], as well as from drosophila larvae [19]. We detected GRP78 in highly enriched hepatic CLD by immunoblot analysis (Figure 2), and we found GRP78 and numerous other chaperone-related proteins on LF- and HF-CLD by proteomic analysis (Table S2). Hepatic GRP78 expression is upregulated in response to ER stress [49], and elements of the ER stress pathway are known to play crucial roles in regulating hepatic lipid metabolism, including lipogenesis [50]. To assess possible LF- and HF-diet refeeding effects on chaperone-CLD interactions in the liver, and better understand the nature of these interactions, we quantified CLD-GRP78 levels in response to LF- and HF-refeeding, and directly investigated the association of GRP78 with CLD in hepatic tissue by IF analysis (Figure 6). The levels of GRP78 in liver homogenates of LF- and HF-refed mice did not differ significantly from each other, or from GRP78 levels found in livers of non-fasted mice, which suggests that hepatic CLD responses are not associated with obvious ER stress. Furthermore, we did not find significant differences in the amount of CLD-associated GRP78 in LF- and HF-refed livers, demonstrating that unlike Plin2, CLD levels of GRP78 are not influenced by diet.
Evidence of direct association between GRP78 and CLD in intact cells has been obtained in adipocytes [51]. To verify that GRP78 directly associates with CLD in intact hepatocytes, we visualized liver sections from fasted mice that were refed with the HF diet and immunostained for Plin2 and GRP78 with laser confocal microscopy (Figure 6D). GRP78 immunostaining was detected in the ER network of hepatocytes and on the surface of their CLD. In contrast to the relatively uniform staining intensity of Plin2 on CLD, GRP78 localized as discrete patches on the CLD surface, in a pattern similar to that described for CLD in adipocytes [51].
Protein disulfide isomerase (PDI) is another prominent ER chaperone protein that was identified by proteomic analysis of hepatic CLD from LF-and HF-refed mice (Table S2). We validated the association of PDI with isolated CLD by immunoblot analysis (data not shown), and confirmed its CLD localization by laser confocal imaging of immunostained stained liver sections (Figure 6E). Similar to GRP78, PDI localized as discrete patches on the surface of Plin2-positive CLD. Collectively, the GRP78 and PDI immunostaining data validate proteomic evidence of ER chaperone protein-CLD association and suggest that chaperones exhibit distinct organizational patterns on the CLD surface.
LF- and HF-refeeding differentially affect CLD levels of the methionine-metabolizing enzyme BHMT
Pathway analysis, revealed significant enrichment of enzymes associated with the cysteine-homocysteine-methionine pathway on liver-CLD (Table 1). Figure 7A, shows the relationship between proteins identified by mass spectrometry and specific steps of the cysteine-methionine metabolism pathway. Betaine homocysteine S-methlytransferase (BHMT), a critical regulatory enzyme of this pathway [52], is an abundant liver protein and one of the top proteomic hits on CLD from LF- and HF-fed mice. In mice, loss of BHMT has been shown to induce hepatosteatosis [53], and high fat feeding has been shown to increase hepatic BHMT transcript levels [54]. We were thus interested in determining if diet affected the amount of BHMT associated with CLD. Figure 7B shows that BHMT levels in whole liver extracts from LF- and HF-refed animals were significantly (77% and 128% respectively) higher than those of non-fasted control animals. Although hepatic BHMT levels in animals refed the HF-diet tended to be higher than those of LF-refed animals, the differences did not reach statistical significance. In contrast, levels of BHMT associated with LF-CLD were about 3-times higher than those associated with HF-CLD when normalized to either total CLD protein, or to CLD-TG content (Figure 7 C and D). These results provide direct evidence for the presence of BHMT on CLD, and demonstrate that its CLD association is altered by diet.
Discussion
Neutral lipid accumulation in the liver, a critical determinant of hepatic lipid homeostasis and liver health [3], [34], [55], is affected by diet and alterations in metabolic function [56], [57]. CLD are responsible for storage and mobilization of neutral lipid stores through the actions of specific surface associated proteins. Although earlier studies have identified proteins associated with hepatic CLD from mice [21], [29], the data presented here provide the first comprehensive non-biased description of the mouse hepatic CLD proteome. The novel findings of this study are that the hepatic CLD protein composition appears to be distinct from that of CLD from other sources; that enzymes of multiple metabolic pathways are associated with hepatic CLD; and that the protein composition of hepatic CLD from fasted and refed mice is qualitatively and quantitatively influenced by dietary fat content, and corresponds to alterations in hepatic metabolic properties. Together, these findings provide evidence that CLD properties are dynamically regulated by the metabolic status of the liver, and that CLD may function in coordinating diverse metabolic activities within liver cells.
The proteins identified in our study were considered to be CLD associated based on their ability to remain bound to CLD through four rounds of floatation isolation. It is possible that using this criterion that at least some of the identified proteins may represent adventitious associations with CLD, especially in the case of low abundance proteins. However, several lines of evidence from our study suggest that the identified proteins are present on CLD as a result of bone fide interactions. First, as shown for VDAC and PEX3, the isolation/wash procedures effectively remove contaminating proteins to levels below that detectable by mass spectrometry. Second, the consistent effects of diet on CLD protein composition cannot be readily explained by simple contamination. Third, the relative abundance of cytoplasmic proteins, such as BHMT, in the final CLD fraction does not correlate with their hepatic levels, as would be expected if their association with CLD was due to adventitious binding. Fourth, proteins such as GRP78 and PDI that have been assumed to represent ER contamination of CLD [20], have been shown to be in close contact with the CLD surface in intact tissues by confocal immunofluoresence microscopy ([51] and Figure 6). Corroboration of the CLD associations of identified proteins will require additional high resolution imaging of hepatic tissue. Alternative methods such as heavy isotope labeling approaches that have been successfully used for proteomic quantification in cultured cells are not practical for in vivo studies [20], particularly for studies involving diet and metabolism in which precursor pools and protein isotope enrichments can be affected [58]. In addition, concepts about CLD protein composition based on biochemical enrichment correlations [20], potentially overlook weaker, mass action driven interactions, that can occur in situ, and possibly exclude interactions that occur with proteins from other cellular compartments [59].
Metabolic functions of hepatic CLD
The primary biological function of CLD is generally understood to be neutral lipid storage, which is thought to involve the integrated actions of ER enzymes and specific CLD-associated proteins [60]. In agreement with this concept, multiple proteomic studies have consistently detected various ER proteins, lipid metabolism enzymes, and members of the PLIN family of CLD-associated proteins on isolated CLD from a variety of mammalian cells and tissues [21]–[31], [48], [61]. There is also growing evidence that CLD may sequester proteins, thereby indirectly contributing to other cellular functions [45]. Our study provides evidence that, at least within the liver, CLD may also function as a platform for coordinating metabolic functions by bringing together elements of specific metabolic pathways. Although additional work is needed to formally establish this concept, we found that the hepatic CLD protein composition is significantly enriched in enzymes composing KEGG pathways related to amino acid, carbohydrate, lipid and xenobiotic metabolism. Further, the identified proteins comprised multiple networks of functionally linked enzymes that, in some cases, correspond to intact portions of metabolic pathways.
CLD properties reflect differences in liver metabolism
Our data indicate that the differential effects of LF- and HF-diet on hepatic CLD protein compositions reflect, in part, differences in hepatic metabolic properties. Indirect calorimetry measurements documented that LF- and HF-refeeding differentially affected the energy metabolism of fasted mice; inducing lipogenesis and the use of carbohydrates for fuel in LF-refed animals, while stimulating the use of fat for fuel in HF-refed animals. Consistent with these metabolic differences, we found a selective enrichment of enzymes involved in amino acid and carbohydrate metabolism, and de novo fatty acid synthesis on LF-CLD. In contrast, enzymes and proteins involved in fatty acid metabolism and lipid transport were enriched on HF-CLD. Additional studies are required to assess the functional importance of these differences. However, it is likely that protein composition differences will reflect subtle modulations of CLD activity, rather than overt changes in their function, since we did not detect large qualitative differences in the protein compositions of LF- and HF-CLD.
This concept is supported by observations that CLD binding of BHMT, a key enzyme in cysteine-methionine metabolism, is differentially affected by dietary fat content and metabolic status of the liver, and is independent of total tissue BHMT levels. In conjunction with evidence that multiple members of the cysteine-methionine metabolic pathway are present on hepatic CLD, the ability of diet to influence CLD-BHMT interactions raises the possibility that CLD may contribute to hepatic metabolic functions by providing a platform for coordinating enzymatic reactions associated with cysteine-methionine metabolism.
Diet induces alterations in CLD surface organization
Diet effects on liver metabolic properties, including transcript expression and protein profiles, have been identified in both long-term and fasting-refeeding studies [32], [33], [62], [63]. There is also increasing recognition that diet influences the molecular properties of hepatic organelles, including mitochondria and ER [64], [65]. Our data expand the effects of diet to include hepatic CLD, documenting directly that the amount of dietary fat affects their molecular properties. The observed effects include alterations in CLD-associated levels of Plin2 and BHMT, both of which are functionally linked to fatty liver formation in mice [8], [53]. Plin2 is a CLD-scaffolding protein [10] that plays an essential role in regulating hepatic lipid accumulation [11], [12]. The finding that HF refeeding increases the CLD surface density of Plin2 provides evidence that its surface organization is dynamically regulated, and that alterations in the surface properties of Plin2 may contribute to its scaffolding and/or lipid storage functions. As yet, it is unclear how diet-induced changes in Plin2 surface density affect hepatic CLD properties. However, we have previously demonstrated that CLD size is decreased in mammary glands of Plin2-deficient mice compared to that of WT mice [66]. Thus, regulating the CLD surface density of Plin2 may be a mechanism for determining CLD size, which in the liver appears to be influenced by dietary fat content.
In summary, our study has described the mouse hepatic CLD proteome, and demonstrated that it is markedly different from proteomes of CLD from other cells and tissues. We have also shown that the hepatic CLD proteome is dynamically influenced by dietary fat content, and related to differences in liver metabolic properties. The proteins found on hepatic CLD are enriched in enzymes with extensive functional connections known to be important for liver metabolism. These findings are consistent with growing evidence that CLD protein compositions are influenced by cellular function, metabolic disorders and/or the physical properties of CLD [14], [15], [24], and they provide support for an expanded role for CLD in regulating cellular metabolic properties beyond that of lipid storage.
Supporting Information
Acknowledgments
The author's thank Brittany Hodges for assistance with mass spectrometry and analysis of proteomic results, and acknowledge services provided by the Adipose Biology Core of the Colorado Obesity Research Initiative, and the Advanced Light Microscopy Core Facility at the University of Colorado School of Medicine and the Boulder 3D Laboratory for Electron Microscopy.
Funding Statement
This research was supported by National Institutes of Health grants 2RO1-HD045962 (JLM), R01DK038088 (PSM), the Colorado Nutrition and Obesity Research Center (NORC, DK48520) and the Colorado Obesity Research Initiative. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
References
- 1. Catenacci VA, Hill JO, Wyatt HR (2009) The obesity epidemic. Clinics in Chest Medicine 30: 415–444. [DOI] [PubMed] [Google Scholar]
- 2. Unger RH, Clark GO, Scherer PE, Orci L (2010) Lipid homeostasis, lipotoxicity and the metabolic syndrome. Biochim Biophys Acta 1801: 209–214. [DOI] [PubMed] [Google Scholar]
- 3. Browning JD, Horton JD (2004) Molecular mediators of hepatic steatosis and liver injury. J Clin Invest 114: 147–152. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4. Fabbrini E, Magkos F, Mohammed BS, Pietka T, Abumrad NA, et al. (2009) Intrahepatic fat, not visceral fat, is linked with metabolic complications of obesity. Proc Natl Acad Sci USA 106: 15430–15435. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5. Stefan N, Kantartzis K, Haring HU (2008) Causes and metabolic consequences of Fatty liver. Endocr Rev 29: 939–960. [DOI] [PubMed] [Google Scholar]
- 6. Bhala N, Angulo P, van der Poorten D, Lee E, Hui JM, et al. (2011) The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: an international collaborative study. Hepatology 54: 1208–1216. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7. Fabbrini E, Sullivan S, Klein S (2010) Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications. Hepatology 51: 679–689. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8. Greenberg AS, Coleman RA, Kraemer FB, McManaman JL, Obin MS, et al. (2011) The role of lipid droplets in metabolic disease in rodents and humans. J Clin Invest 121: 2102–2110. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9. Tauchi-Sato K, Ozeki S, Houjou T, Taguchi R, Fujimoto T (2002) The surface of lipid droplets is a phospholipid monolayer with a unique Fatty Acid composition. J Biol Chem 277: 44507–44512. [DOI] [PubMed] [Google Scholar]
- 10. Brasaemle DL (2007) The perilipin family of structural lipid droplet proteins: Stabilization of lipid droplets and control of lipolysis. The Journal of Lipid Research 48: 2547–2549. [DOI] [PubMed] [Google Scholar]
- 11. Chang BH, Li L, Paul A, Taniguchi S, Nannegari V, et al. (2006) Protection against fatty liver but normal adipogenesis in mice lacking adipose differentiation-related protein. Mol Cell Biol 26: 1063–1076. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12. Imai Y, Varela GM, Jackson MB, Graham MJ, Crooke RM, et al. (2007) Reduction of hepatosteatosis and lipid levels by an adipose differentiation-related protein antisense oligonucleotide. Gastroenterology 132: 1947–1954. [DOI] [PubMed] [Google Scholar]
- 13. McManaman JL, Bales ES, Orlicky DJ, Jackman M, MacLean PS, et al. (2013) Perilipin-2-null mice are protected against diet-induced obesity, adipose inflammation, and fatty liver disease. The Journal of Lipid Research 54: 1346–1359. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14. Straub BK, Stoeffel P, Heid H, Zimbelmann R, Schirmacher P (2008) Differential pattern of lipid droplet-associated proteins and de novo perilipin expression in hepatocyte steatogenesis. Hepatology 47: 1936–1946. [DOI] [PubMed] [Google Scholar]
- 15. Orlicky DJ, Roede JR, Bales E, Greenwood C, Greenberg A, et al. (2011) Chronic ethanol consumption in mice alters hepatocyte lipid droplet properties. Alcohol Clin Exp Res 35: 1020–1033. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16. Athenstaedt K, Zweytick D, Jandrositz A, Kohlwein SD, Daum G (1999) Identification and characterization of major lipid particle proteins of the yeast Saccharomyces cerevisiae. J Bacteriol 181: 6441–6448. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17. Binns D, Januszewski T, Chen Y, Hill J, Markin VS, et al. (2006) An intimate collaboration between peroxisomes and lipid bodies. J Cell Biol 173: 719–731. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18. Cermelli S, Guo Y, Gross SP, Welte MA (2006) The lipid-droplet proteome reveals that droplets are a protein-storage depot. Curr Biol 16: 1783–1795. [DOI] [PubMed] [Google Scholar]
- 19. Beller M, Riedel D, Jansch L, Dieterich G, Wehland J, et al. (2006) Characterization of the Drosophila lipid droplet subproteome. Mol Cell Proteomics 5: 1082–1094. [DOI] [PubMed] [Google Scholar]
- 20.Krahmer N, Hilger M, Kory N, Wilfling F, Stoehr G, et al.. (2013) Protein Correlation Profiles Identify Lipid Droplet Proteins with High Confidence. Mol Cell Proteomics. doi:10.1074/mcp.M112.020230. [DOI] [PMC free article] [PubMed]
- 21. Wu CC, Howell KE, Neville MC, Yates JR 3rd, McManaman JL (2000) Proteomics reveal a link between the endoplasmic reticulum and lipid secretory mechanisms in mammary epithelial cells. Electrophoresis 21: 3470–3482. [DOI] [PubMed] [Google Scholar]
- 22. Liu P, Ying Y, Zhao Y, Mundy DI, Zhu M, et al. (2004) Chinese hamster ovary K2 cell lipid droplets appear to be metabolic organelles involved in membrane traffic. J Biol Chem 279: 3787–3792. [DOI] [PubMed] [Google Scholar]
- 23. Bartz R, Zehmer JK, Zhu M, Chen Y, Serrero G, et al. (2007) Dynamic activity of lipid droplets: protein phosphorylation and GTP-mediated protein translocation. J Proteome Res 6: 3256–3265. [DOI] [PubMed] [Google Scholar]
- 24. Brasaemle DL, Dolios G, Shapiro L, Wang R (2004) Proteomic analysis of proteins associated with lipid droplets of basal and lipolytically stimulated 3T3-L1 adipocytes. J Biol Chem 279: 46835–46842. [DOI] [PubMed] [Google Scholar]
- 25. Cho SY, Shin ES, Park PJ, Shin DW, Chang HK, et al. (2007) Identification of mouse Prp19p as a lipid droplet-associated protein and its possible involvement in the biogenesis of lipid droplets. J Biol Chem 282: 2456–2465. [DOI] [PubMed] [Google Scholar]
- 26. Umlauf E, Csaszar E, Moertelmaier M, Schuetz GJ, Parton RG, et al. (2004) Association of stomatin with lipid bodies. J Biol Chem 279: 23699–23709. [DOI] [PubMed] [Google Scholar]
- 27. Fujimoto Y, Itabe H, Sakai J, Makita M, Noda J, et al. (2004) Identification of major proteins in the lipid droplet-enriched fraction isolated from the human hepatocyte cell line HuH7. Biochim Biophys Acta 1644: 47–59. [DOI] [PubMed] [Google Scholar]
- 28. Sato S, Fukasawa M, Yamakawa Y, Natsume T, Suzuki T, et al. (2006) Proteomic profiling of lipid droplet proteins in hepatoma cell lines expressing hepatitis C virus core protein. J Biochem 139: 921–930. [DOI] [PubMed] [Google Scholar]
- 29. Turro S, Ingelmo-Torres M, Estanyol JM, Tebar F, Fernandez MA, et al. (2006) Identification and characterization of associated with lipid droplet protein 1: A novel membrane-associated protein that resides on hepatic lipid droplets. Traffic 7: 1254–1269. [DOI] [PubMed] [Google Scholar]
- 30. Wan HC, Melo RC, Jin Z, Dvorak AM, Weller PF (2007) Roles and origins of leukocyte lipid bodies: proteomic and ultrastructural studies. The FASEB Journal 21: 167–178. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31. Zhang H, Wang Y, Li J, Yu J, Pu J, et al. (2011) Proteome of skeletal muscle lipid droplet reveals association with mitochondria and apolipoprotein a-I. J Proteome Res 10: 4757–4768. [DOI] [PubMed] [Google Scholar]
- 32. Sokolovic M, Sokolovic A, Wehkamp D, Ver Loren van Themaat E, de Waart DR, et al. (2008) The transcriptomic signature of fasting murine liver. BMC Genomics 9: 528. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33. Zhang F, Xu X, Zhou B, He Z, Zhai Q (2011) Gene expression profile change and associated physiological and pathological effects in mouse liver induced by fasting and refeeding. PLoS ONE 6: e27553. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34. Boer den M, Voshol PJ, Kuipers F, Havekes LM, Romijn JA (2004) Hepatic steatosis: a mediator of the metabolic syndrome. Lessons from animal models. Arterioscler Thromb Vasc Biol 24: 644–649. [DOI] [PubMed] [Google Scholar]
- 35. Bergen WG, Mersmann HJ (2005) Comparative aspects of lipid metabolism: impact on contemporary research and use of animal models. J Nutr 135: 2499–2502. [DOI] [PubMed] [Google Scholar]
- 36. Russell TD, Palmer CA, Orlicky DJ, Bales ES, Chang BH-J, et al. (2008) Mammary glands of adipophilin-null mice produce an amino-terminally truncated form of adipophilin that mediates milk lipid droplet formation and secretion. The Journal of Lipid Research 49: 206–216. [DOI] [PubMed] [Google Scholar]
- 37. Wahlig JL, Bales ES, Jackman MR, Johnson GC, Mcmanaman JL, et al. (2012) Impact of High-Fat Diet and Obesity on Energy Balance and Fuel Utilization During the Metabolic Challenge of Lactation. Obesity 20: 65–75. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 38. Russell TD, Palmer CA, Orlicky DJ, Fischer A, Rudolph MC, et al. (2007) Cytoplasmic lipid droplet accumulation in developing mammary epithelial cells: roles of adipophilin and lipid metabolism. The Journal of Lipid Research 48: 1463–1475. [DOI] [PubMed] [Google Scholar]
- 39. Lei TC, Ammar DA, Masihzadeh O, Gibson EA, Kahook MY (2011) Label-free imaging of trabecular meshwork cells using Coherent Anti-Stokes Raman Scattering (CARS) microscopy. Mol Vis 17: 2628–2633. [PMC free article] [PubMed] [Google Scholar]
- 40. Tokuyasu KT (1986) Application of cryoultramicrotomy to immunocytochemistry. J Microscopy 143: 139–149. [DOI] [PubMed] [Google Scholar]
- 41. Chong BM, Russell TD, Schaack J, Orlicky DJ, Reigan P, et al. (2011) The adipophilin C-terminus is a self-folding membrane binding domain that is important for milk lipid secretion. J Biol Chem. 286: 23254–23265. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 42. Lissner L, Levitsky DA, Strupp BJ, Kalkwarf HJ, Roe DA (1987) Dietary fat and the regulation of energy intake in human subjects. Am J Clin Nutr 46: 886–892. [DOI] [PubMed] [Google Scholar]
- 43. Parks EJ, Hellerstein MK (2006) Thematic review series: patient-oriented research. Recent advances in liver triacylglycerol and fatty acid metabolism using stable isotope labeling techniques. The Journal of Lipid Research 47: 1651–1660. [DOI] [PubMed] [Google Scholar]
- 44. Nan X, Potma EO, Xie XS (2006) Nonperturbative chemical imaging of organelle transport in living cells with coherent anti-stokes Raman scattering microscopy. Biophysical journal 91: 728–735. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 45. Hodges BD, Wu CC (2010) Proteomic insights into an expanded cellular role for cytoplasmic lipid droplets. The Journal of Lipid Research 51: 262–273. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 46. Dalen KT, Ulven SM, Arntsen BM, Solaas K, Nebb HI (2006) PPARalpha activators and fasting induce the expression of adipose differentiation-related protein in liver. The Journal of Lipid Research 47: 931–943. [DOI] [PubMed] [Google Scholar]
- 47. Orlicky DJ, Degala G, Greenwood C, Bales ES, Russell TD, et al. (2008) Multiple functions encoded by the N-terminal PAT domain of adipophilin. J Cell Sci 121: 2921–2929. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 48. Ding Y, Wu Y, Zeng R, Liao K (2012) Proteomic profiling of lipid droplet-associated proteins in primary adipocytes of normal and obese mouse. Acta biochimica et biophysica Sinica 44: 394–406. [DOI] [PubMed] [Google Scholar]
- 49. Yoshiuchi K, Kaneto H, Matsuoka TA, Kasami R, Kohno K, et al. (2009) Pioglitazone reduces ER stress in the liver: direct monitoring of in vivo ER stress using ER stress-activated indicator transgenic mice. Endocrine Journal 56: 1103–1111. [DOI] [PubMed] [Google Scholar]
- 50. Lee AH, Scapa EF, Cohen DE, Glimcher LH (2008) Regulation of hepatic lipogenesis by the transcription factor XBP1. Science 320: 1492–1496. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 51. Prattes S, Horl G, Hammer A, Blaschitz A, Graier WF, et al. (2000) Intracellular distribution and mobilization of unesterified cholesterol in adipocytes: triglyceride droplets are surrounded by cholesterol-rich ER-like surface layer structures. J Cell Sci 113: 2977–2989. [DOI] [PubMed] [Google Scholar]
- 52. Finkelstein JD (2003) Methionine metabolism in liver diseases. Am J Clin Nutr 77: 1094–1095. [DOI] [PubMed] [Google Scholar]
- 53. Teng YW, Mehedint MG, Garrow TA, Zeisel SH (2011) Deletion of betaine-homocysteine S-methyltransferase in mice perturbs choline and 1-carbon metabolism, resulting in fatty liver and hepatocellular carcinomas. J Biol Chem 286: 36258–36267. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 54. Rubio-Aliaga I, Roos B, Sailer M, McLoughlin GA, Boekschoten MV, et al. (2011) Alterations in hepatic one-carbon metabolism and related pathways following a high-fat dietary intervention. Physiological Genomics 43: 408–416. [DOI] [PubMed] [Google Scholar]
- 55. Yamaguchi K, Yang L, McCall S, Huang J, Yu XX, et al. (2007) Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis. Hepatology 45: 1366–1374. [DOI] [PubMed] [Google Scholar]
- 56. Begriche K, Massart J, Robin MA, Borgne-Sanchez A, Fromenty B (2011) Drug-induced toxicity on mitochondria and lipid metabolism: mechanistic diversity and deleterious consequences for the liver. J Hepatol 54: 773–794. [DOI] [PubMed] [Google Scholar]
- 57. Nagle CA, Klett EL, Coleman RA (2009) Hepatic triacylglycerol accumulation and insulin resistance. The Journal of Lipid Research 50 Suppl: S74–S79 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 58. Wu CC, MacCoss MJ, Howell KE, Matthews DE, Yates JR (2004) Metabolic labeling of mammalian organisms with stable isotopes for quantitative proteomic analysis. Anal Chem 76: 4951–4959. [DOI] [PubMed] [Google Scholar]
- 59. Li Z, Thiel K, Thul PJ, Beller M, Kühnlein RP, et al. (2012) Lipid droplets control the maternal histone supply of Drosophila embryos. Curr Biol 22: 2104–2113. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 60. Ohsaki Y, Cheng J, Suzuki M, Shinohara Y, Fujita A, et al. (2009) Biogenesis of cytoplasmic lipid droplets: from the lipid ester globule in the membrane to the visible structure. Biochim Biophys Acta 1791: 399–407. [DOI] [PubMed] [Google Scholar]
- 61. Bouchoux J, Beilstein F, Pauquai T, Guerrera IC, Chateau D, et al. (2011) The proteome of cytosolic lipid droplets isolated from differentiated Caco-2/TC7 enterocytes reveals cell-specific characteristics. Biol Cell 103: 499–517. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 62. Kirpich IA, Gobejishvili LN, Bon Homme M, Waigel S, Cave M, et al. (2011) Integrated hepatic transcriptome and proteome analysis of mice with high-fat diet-induced nonalcoholic fatty liver disease. J Nutr Biochem 22: 38–45. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 63. Oh TS, Kwon EY, Choi JW, Choi MS, Yun JW (2011) Time-dependent hepatic proteome analysis in lean and diet-induced obese mice. Journal of Microbiology and Biotechnology 21: 1211–1227. [DOI] [PubMed] [Google Scholar]
- 64. Grimsrud PA, Carson JJ, Hebert AS, Hubler SL, Niemi NM, et al. (2012) A quantitative map of the liver mitochondrial phosphoproteome reveals posttranslational control of ketogenesis. Cell Metab 16: 672–683. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 65. Fu S, Fan J, Blanco J, Gimenez-Cassina A, Danial NN, et al. (2012) Polysome profiling in liver identifies dynamic regulation of endoplasmic reticulum translatome by obesity and fasting. PLoS Genetics 8: e1002902. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 66. Russell TD, Schaack J, Orlicky DJ, Palmer C, Chang BH-J, et al. (2011) Adipophilin regulates maturation of cytoplasmic lipid droplets and alveolae in differentiating mammary glands. J Cell Sci 124: 3247–3253. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.